Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Want to cut your energy bills? Here’s how five experts are doing it 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
STAMFORD, Conn., March 02, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, March 9, 2017, at 4:30 p.m. ET to report fourth quarter and full year 2016 financial results and provide a corporate update.
To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 70053458. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
